By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


SEARCH JOBS

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.

YEAR FOUNDED:

1840

LEADERSHIP:

Founder: Emil Mallinckrodt

CEO: Mark Trudeau

CFO: Matthew Harbaugh

JOBS:

Please click here for Mallinckrodt job opportunities.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Mallinckrodt
Employees:
Symbol: MNK
 



Industry
Medical Device


Collaborations

Advanced Magnetics, Inc.  GastroMARK in North America





Company News
Mallinckrodt (MNK) Receives FDA Fast-Track Designation For Synacthen Depot IND Application 8/25/2016 9:09:46 AM
Mallinckrodt (MNK) Selling Nuclear Imaging Biz to IBA Molecular in $690 Million Deal 8/24/2016 6:24:54 AM
Extracorporeal Photopheresis (ECP), Including Mallinckrodt (MNK)'s THERAKOS ECP Immunomodulation, Receives Approval For Reimbursement By Swiss Federal Department Of Home Affairs 8/23/2016 9:44:02 AM
Mallinckrodt (MNK) To Present At Wells Fargo Securities Healthcare Conference 8/19/2016 8:12:30 AM
Mallinckrodt (MNK) to Build New $80 Million+ Campus in New Jersey With Space for 400 Employees 8/18/2016 6:38:58 AM
Covidien (COV) Spinout Mallinckrodt (MNK) to Acquire Skin Substitute Developer Stratatech 8/11/2016 7:41:36 AM
Mallinckrodt (MNK) Reports Fiscal 2016 Third Quarter Results And Provides Guidance For Calendar Year 2016 8/2/2016 7:46:27 AM
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016 6:14:25 AM
Mallinckrodt (MNK) Warned Over Missing Study About Child Opioids Use 7/8/2016 6:54:42 AM
National Pharmaceutical Council Welcomes Mallinckrodt (MNK) As Its Newest Member 6/23/2016 7:27:58 AM
12345678910...
//-->